1. Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice. A, Immunoblotting of BAX and BAK in sublines isolated from RS4;11 xenografts treated with ABT-263 first followed by a second treatment with either ABT-263 or SAR B, Immunoblotting of BAX and BAK in sublines isolated from RS4;11 xenografts treated with SAR first followed by a second treatment with either ABT-263 or SAR C, Antitumor activity of RS4;11 xenografts treated with ABT-263 for 21 days at 100 mg/kg orally (top) and body weight of mice during second round of treatment (bottom). D, Antitumor activity of RS4;11 xenografts treated with SAR for 21 days at 100 mg/kg orally (top) and body weight of mice during second round of treatment (bottom). A
30R A1M A2M A4M A7M A3A A5A B
A#M
1st: 100 mg/kg ABT-263
2nd : 100 mg/kg SAR
RS4; L 30R M16M M7A M9A M13A M14A
M16M
1st : 100 mg/kg SAR
2nd : 200 mg/kg SAR
BAX
BAX
BAK
A#A
1st: 100 mg/kg ABT-263
2nd : 150 mg/kg ABT-263
BAK
M#A
1st : 100 mg/kg SAR
2nd : 100 mg/kg ABT-263
GAPDH
GAPDH C D